Strengthening Translational & Clinical Development of a New Wave of Genetic, Stem Cell, Small Molecule & RNA-Based Muscle Disease Therapies
After a year marked by uncertainty around Sarepta's Elevidys, the field is on the verge of new era shaped by cross-modality innovation and meaningful progress, with FDA submissions anticipated from Regenxbio, Capricor and Avidity that could transform therapeutic options for muscular dystrophies.
With investments including Servier’s $2.65 billion buyout of Edgewise signposting reignited pharma interest and funding opportunities, muscle disease drug developers are poised to double down on investments across their preclinical, translational and clinical programs in 2026 and beyond.
Take advantage of this timely opportunity to join 60+ industry experts spanning muscle disease biology, translation, clinical development and more at the Muscular Disorders Drug Development Summit for three days of focused collaboration designed to:
- Explore emerging modalities beyond gene therapy
- Discover lessons learnt from developers of approved drugs
- Enhance biomarker measurements of muscular function and activity
- Innovate more targeted delivery to specific muscles while avoiding off-target tissues
- Leverage real-world data to uncover patient-relevant endpoints
With momentum building, don’t miss your chance to learn from Servier, Dyne Therapeutics, Sanofi, Biogen, Avidity Biosciences and more at the only forum dedicated to addressing biopharma’s most pressing challenges in advancing novel therapies for muscular dystrophies, Pompe disease and related myopathies.
Hear From Industry Peers:
Attending Companies Include
Covering the Full Spectrum of Muscular Disorders Drug Development
From Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) to myotonic dystrophy (DM1), limb-girdle muscular dystrophy (LGMD), Pompe disease, and related myopathies, the Muscular Disorders Drug Development Summit brings together leaders driving innovation across the muscular disease landscape. Explore shared development challenges, indication-specific insights, and opportunities to accelerate therapeutic advancement across multiple disease areas.
Official Partners
Pre-Conference Workshop Day
Join experts from leading biotech and pharma organizations already attending the workshop day, including Sanofi, PTC, Edgewise, Lundbeck & UCB to tackle shared translational and clinical development challenges across muscular disorders. Secure valuable networking opportunities ahead of the main conference and gain practical insights that can strengthen your development strategy.
Get ahead of the networking and build meaningful relationships before the main conference begins
Engage directly with peers tackling muscular dystrophy, Pompe disease and related myopathy development challenges
Collaboratively discuss clinical trial design, biomarker strategy, endpoint selection and translational hurdles
Exchange lessons learned across gene therapy, RNA therapeutics, stem cell approaches and small molecules
Leave with actionable insights from content not available within the main conference agenda, to accelerate your own development programs
Maximize your three-day experience by establishing valuable connections early